{"id":"NCT01614886","sponsor":"Novartis Pharmaceuticals","briefTitle":"Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","officialTitle":"A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2012-06-08","resultsPosted":"2015-05-12","lastUpdate":"2016-08-01"},"enrollment":216,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Active Comparator","otherNames":[]},{"type":"DRUG","name":"ENA713","otherNames":[]}],"arms":[{"label":"1 step","type":"EXPERIMENTAL"},{"label":"3 step","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the tolerability, safety and efficacy of 3-step titration versus 1-step titration of Rivastigmine patch in the Japanese population.","primaryOutcome":{"measure":"Percentage of Patients With Adverse Events Leading to Study Drug Discontinuation","timeFrame":"Up to 24 weeks","effectByArm":[{"arm":"Rivastigmine Patch 1 Step","deltaMin":15,"sd":null},{"arm":"Rivastigmine Patch 3 Step","deltaMin":18.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":50,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":107},"commonTop":["Application site pruritus","Application site erythema","Dermatitis contact","Nasopharyngitis","Nausea"]}}